Clinical trials: Type I Diabetes
Diabetes, Diabetes Mellitus, Type 1
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
The trial is conducted in Europe and Middle East. The aim of the trial is to compare the use of Insulin Detemir once or twice daily combined with mealtime Insulin Aspart against that of NPH Insulin once or twice daily combined…
- Trial name
- NCT00312156
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 42 sites in Belgium, Croatia and 14 more
- Volunteers
- 347 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Diabete Type 2
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction.
- Trial name
- NCT07563699
- Testing
- SG Depot 2 mg, SG Depot 4 mg, SG Depot 6 mg
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Mapi Pharma Ltd.
Hypoglycemia, Diabetes Mellitus, Type 1
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1…
- Trial name
- NCT02656069
- Testing
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Where
- 7 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus, High Blood Sugar
A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients
The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.
- Trial name
- NCT01221519
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05644730
- Testing
- Fusion closed loop glucose control system
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ideal Medical Technologies
Diabetes, Diabetes Mellitus, Type 1
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
- Trial name
- NCT00071448
- Testing
- insulin human, insulin lispro, insulin aspart
- Where
- 76 sites in United States
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Trial name
- NCT00332826
- Testing
- Technosphere Insulin
- Where
- 78 sites in United States, Argentina and 9 more
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus
- Trial name
- NCT01222078
- Testing
- otelixizumab
- Where
- 2 sites in France, Germany
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin.
- Trial name
- NCT03449433
- Testing
- LY900014, Insulin Lispro, Insulin Aspart
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes
The purpose of this study is to collect data on the feasibility of the HLCL system in a camp setting.
- Trial name
- DREAMED (NCT02692547)
- Testing
- Hybrid-logic closed loop system
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Twiist Postmarket Surveillance Study for Type 1 Diabetes
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
- Trial name
- twiist-PS (NCT07356089)
- Testing
- twiist Automated Insulin Delivery System
- Where
- United States
- Volunteers
- 1,875 people
- Sponsor
- Deka Research and Development
Diabetes Mellitus, Type 1
Extended Wear of a Steel and a Teflon Insulin Infusion Set
This is a cross-over study to evaluate if insulin infusion sets can be used up to 7 days.
- Trial name
- NCT03683368
- Testing
- YpsoPump Orbit soft, YpsoPump Orbit micro
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT03302234
- Testing
- Pembrolizumab, Ipilimumab
- Where
- 187 sites in United States, Argentina and 22 more
- Volunteers
- 568 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body)…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Healthy
- Trial name
- NCT01730014
- Testing
- 148-0287-A-4.2mM-cartridge, insulin glargine, sodium chloride 0.9% w/v
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Evaluation of TTP399 in Patients With Type 1 Diabetes
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing.
- Trial name
- SimpliciT1 (NCT03335371)
- Testing
- TTP399
- Where
- 15 sites in United States
- Volunteers
- 115 people
- Sponsor
- vTv Therapeutics
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.